WO2005024057A1 - Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule - Google Patents

Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule Download PDF

Info

Publication number
WO2005024057A1
WO2005024057A1 PCT/EP2003/010160 EP0310160W WO2005024057A1 WO 2005024057 A1 WO2005024057 A1 WO 2005024057A1 EP 0310160 W EP0310160 W EP 0310160W WO 2005024057 A1 WO2005024057 A1 WO 2005024057A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
group
compound
amyloid
Prior art date
Application number
PCT/EP2003/010160
Other languages
English (en)
Inventor
Pascal Gerard Merchiers
Koenraad Frederik Florentina Spittaels
Marcel Hoffmann
Kim Thys
Wendy Laenen
Original Assignee
Galapagos Genomics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics N.V. filed Critical Galapagos Genomics N.V.
Priority to PCT/EP2003/010160 priority Critical patent/WO2005024057A1/fr
Priority to AU2003267347A priority patent/AU2003267347A1/en
Priority to PCT/EP2004/010172 priority patent/WO2005024058A2/fr
Publication of WO2005024057A1 publication Critical patent/WO2005024057A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • the present invention relates to methods of identifying a compound that changes the amyloid-beta precursor protein processing in a cell.
  • the invention also relates to methods for changing the amyloid-beta precursor protein processing of a cell.
  • AD Alzheimer ' s disease
  • the patients finally fall into a severely debilitated, immobile state between 4 and 12 years after onset of the disease.
  • AD Alzheimer's disease
  • PS1 presenilin 1 and 2
  • APP amyloid-beta precursor protein
  • amyloid beta 1-42 peptides form amyloid fibrils more readily than the amyloid beta 1-40 peptides, which are predominantly produced in healthy people. These insoluble, amyloid fibrils are then deposited in the amyloid plaques.
  • the amyloid beta peptides are generated from the membrane anchored APP, after cleavage by beta secretase and gamma secretase at position 1 and 42, respectively ( Figure 1) (Annaert and De Strooper (2002)).
  • the gamma secretase can also cleave at position 40.
  • high activity of beta secretase results in a shift of the cleavage at position 1 to position 11.
  • Beta secretase was identified as the membrane anchored aspartyl protease BACE, while gamma secretase is a protein complex comprising presenilin 1 (PSl) or presenilin 2 (PS2) , nicastrin, Anterior Pharynx Defective 1 (APHl) and Presenilin Enhancer 2 (PEN2) .
  • PSl presenilin 1
  • PS2 presenilin 2
  • PEN2 Anterior Pharynx Defective 1
  • PEN2 Presenilin Enhancer 2
  • the presenilins are widely thought to constitute the catalytic activity of the gamma secretase, while the other components play a role in the maturation and localization of the complex.
  • the identity of the alpha secretase is still illustrious, although some results point towards the proteases ADAM 10 and TACE, which could have redundant functions . It has been shown that injection of amyloid beta fibrils in the brains of P301L tau transgenic mice enhances the formation of neurofibrillary tangles, placing the amyloid beta peptide on top of the neurotoxic cascade (Gotz et al . (2001) ) .
  • AD therapies are focused on the inhibition of the acetylcholinesterase enzyme, leading to an increased concentration of the acetylcholine..However, this therapy does not halt the progression of the disease.
  • therapies aimed at decreasing the levels of amyloid beta peptides in the brain are heavily investigated and will become very important. Most of these therapies are focused on the perturbed amyloid-beta precursor protein processing and target directly beta- or gamma secretase activity. However, targeting these proteins has not yielded any new drugs yet, because of the difficulty to find specific drugs and the suspected serious side effects.
  • amyloid-beta precursor protein processing pathway is of great interest, since this would allow a direct interference with the production of the pathological amyloid beta 1-42 peptide, which should block the neurotoxic cascade induced by the latter.
  • the present invention relates to a method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell, comprising: (a) providing a host cell expressing a polypeptide having a amino acid sequence selected from the group consisting of SEQ ID NO: 15-28, or a fragment, or a derivative thereof; (b) determining a first activity level of the polypeptide by measuring the level of one or more second messengers of the polypeptide; (c) exposing the host cell to a compound; (d) determining a second activity level of the polypeptide by measuring the level of the second messengers after exposing of the host cell to the compound; and (e) identifying the compound by which the second activity level is less than the first activity level.
  • the polypeptides of this invention when overexpressed or activated, induce the level of secreted amyloid beta 1-42, amyloid beta 1-40, and amyloid beta 1-x, where x ranges from 19-42.
  • the amyloid beta peptides 1-42, 1-40, 1- 39, 1-38, 1-37 are often seen in the cerebral spinal fluid.
  • the level of these amyloid beta peptides in Alzheimer patients is increased compared to the levels of these peptides in healthy persons.
  • the amyloid beta peptides 1-42, 1-40, 1-39, 1-38, 1-37 can be found in plaques. Thus, reducing the levels of these amyloid beta peptide is beneficial for patients with cognitive impairment.
  • the polypeptides of this invention are G-protein coupled receptors (GPCRs) and can be inhibited by small molecules. All GPCRs share a common architecture of 7 transmembrane domains, an extracellular N-terminus and an intracellular C- terminus .
  • GPCRs G-protein coupled receptors
  • All GPCRs share a common architecture of 7 transmembrane domains, an extracellular N-terminus and an intracellular C- terminus .
  • the major signal transduction cascades activated by GPCRs are initiated by the activation of heterotrimeric G- proteins (Wess (1998)), built from three different proteins; the G ⁇ , G ⁇ and G ⁇ subunits. The signal transduction cascade starts with the activation of the receptor by an agonist.
  • Transformational changes in the receptor are then translated down to the G-protein.
  • the G-protein dissociates into the G ⁇ subunit and the G ⁇ V subunit . Both subunits dissociate from the receptor and are both capable of initiating different cellular responses. Best known are the cellular effects that are initiated by the G ⁇ subunit. It is for this reason that G-proteins are categorized by their G ⁇ subunit.
  • the G- proteins are divided into four groups: G s ,G i/o , G q and G ⁇ 2 / ⁇ 3 . Each of these G-proteins is capable of activating an effector protein, which results in changes in second messenger levels in the cell. The changes in second messenger level are the triggers that make the cell respond to the extracellular signal in a specific manner.
  • the activity of a GPCR can be measured by measuring the activity level of the second messenger.
  • the two most important second messengers in the cell are cAMP and Ca 2+ .
  • the ⁇ -subunit of the G s class of G-proteins is able to activate adenylyl cyclase, resulting in an increased turnover from ATP to cAMP.
  • the ⁇ -subunit of Gi 0 G-proteins does exactly the opposite and inhibits adenylyl cyclase activity resulting in a decrease of cellular cAMP levels. Together, these two classes of G-proteins regulate the second messenger cAMP.
  • Ca 2+ is regulated by the ⁇ -subunit of the G q class of G-proteins.
  • Inositol 1, 4, 5-trisphosphate binds specific receptors in the endoplasmatic reticulum, resulting in the opening of Ca 2+ channels and release of Ca 2+ in the cytoplasm.
  • Second messenger activation can be measured by several different techniques, either directly by ELISA or radioactive technologies or indirectly by reporter gene analysis.
  • a host cell expressing a polypeptide of the present invention can be a cell with endogenous expression of the polypeptide or a cell overexpressing the polypeptide e.g. by transduction.
  • endogenous expression of the polypeptide of the present invention is not sufficient for a first activity level of the second measure that can easily be measured, overexpression of the polypeptide can be applied.
  • Overexpression has the advantage that the first activity level of the second messenger is higher than the activity level by endogenous expression.
  • the method according to the present invention further comprises contacting the host cell with an agonist for the polypeptide before determining the first activity level.
  • the addition of an agonist further stimulates the polypeptides of the present invention, thereby further increasing the activity level of the second messenger.
  • Another embodiment relates to the method according to the present invention further comprising (f) contacting a population of mammalian cells expressing a polypeptide having a amino acid sequences selected from the group consisting of SEQ ID NO: 15-28, or a fragment, or a derivative thereof, with the compound identified in step (e) ; and (g) identifying the compound that changes the amyloid-beta precursor protein processing in the cells.
  • Amyloid-beta precursor protein is processed into several different amyloid beta peptides species. According to the invention, mompounds are identified that change the APP processing and reduce the level of secreted pathological amyloid beta peptides.
  • Levels of amyloid beta peptides can be measured with specific ELISA' s using antibodies specifically recognizing the different amyloid beta peptide species (see e.g. Example 1). Levels of amyloid beta peptides can also be measured by Mass spectrometry analysis (see e.g. Example 7).
  • the polypeptide is FPRL1, as defined by SEQ ID NO: 15.
  • the polypeptide is GCGR, as defined by SEQ ID NO: 22.
  • the activity level is determined with a reporter controlled by a promoter, which is responsive to the second messenger.
  • the reporter is a reporter gene under the regulation of a promoter that responds to the cellular level of second messengers.
  • the reporter gene has a gene product that is easily detected. Reporter genes can be easily transferred to host cells by persons of ordinary skill in the art. The reporter gene can be stably infected in the host cell.
  • the reporter gene may be selected from the group comprising: alkaline phosphatase, enhanced green fluorescent protein, destabilized green fluorescent protein, luciferase or ⁇ - galactosidase .
  • the promoter is a cyclic AMP-responsive promoter, a NF-KB responsive promoter, or a NF-AT responsive promoter.
  • the cyclic-AMP responsive promoter is responsive for the cyclic-AMP levels in the cell.
  • the NF-AT responsive promoter is sensitive to cytoplasmic Ca 2+ -levels in the cell.
  • the NF-KB responsive promoter is sensitive for activated NF- KB levels in the cell.
  • the reporter is luciferase or ⁇ - galactosidase .
  • Luciferase and ⁇ -galactosidase are easily available and have a large dynamic range for measuring. In addition, luciferase and ⁇ -galactosidase are less expensive which is favorable especially when performing the method of the present invention in a high throughput format.
  • the present invention further relates to a method for identifying a compound that changes the amyloid-beta precursor protein processing in a cell, comprising: (a) contacting one or more compounds with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15-28, or a derivative, or a fragment thereof, (b) determining the binding affinity of the compound to the polypeptide, (c) contacting a population of mammalian cells expressing the polypeptide with the compound that exhibits a binding affinity of at least 10 micromolar, and (d) identifying the compound that changes the amyloid-beta precursor protein processing in the cells.
  • the present invention relates to a method for identifying a compound that changes the amyloid-beta precursor protein processing in cells, comprising:
  • the binding affinity of the compound to the polypeptide or polynucleotide can be measured by methods known in the art, such as using surface plasmon resonance biosensors (Biacore) , by saturation binding analysis with a labeled compound (e.g. Scatchard and Lindmo analysis), by differential UV spectrophotometer, fluorescence polarisation assay, Fluorometric Imaging Plate Reader (FLIPR ® ) system, Fluorescence resonance energy transfer, and Bioluminescence resonance energy transfer.
  • the binding affinity of compounds can also be expressed in a dissociation constant (Kd) or as IC50 or EC50.
  • the IC50 represents the concentration of a compound that is required for 50% inhibition of binding of another ligand to the polypetide.
  • the EC50 represents the concentration required for obtaining 50% of the maximum effect in any assay that measures receptor function.
  • the dissociation constant, Kd is a measure of how well a ligand binds to the polypeptide , it is equivalent to the ligand concentration required to saturate exactly half of the binding-sites on the polypeptide.
  • Compounds with a high affinity binding have low Kd, IC50 and EC50 values, i.e. in the range of 100 nM to 1 pM; a moderate to low affinity binding relates to a high Kd, IC50 and EC50 values, i.e.
  • Changing the APP processing according to the present invention relates to the reduction of the level of amyloid beta peptide 1-x, whereby x ranges from 19-42 and/or the increase of the level of amyloid beta peptide y-42, whereby y ranges from 1-24.
  • the changes in amyloid beta peptide levels can be measured by e.g. an ELISA with specific antibodies as explained in example 1 or by mass spectrometry analysis (example 7) .
  • libraries of compounds can be used such as peptide libraries (e.g. LOPAPTM, Sigma Aldrich) , lipid libraries (BioMol) , synthetic compound libraries (e.g.
  • the compounds are low molecular weight compounds.
  • Low molecular weight compounds i.e. with a molecular weight of 500 Dalton or less, are likely to have good absorption and permeation in biological systems and are consequently more likely to be successful drug candidates than compounds with a molecular weight above 500 Dalton (Lipinski et al. (1997)).
  • the compounds are peptides. Many GPCRs have a peptide as an antagonist. Peptides can be excellent drug candidates and there are multiple examples of commercially valuable peptides such as fertility hormones and platelet aggregation inhibitors.
  • the compounds are natural compounds . Natural compounds are compounds that have been extracted from e.g. plants or compounds that are synthesized on the basis of a natural occurring molecule.
  • the compounds are lipids.
  • GPCRs listed in table 1 can have lipids as antagonists. Using lipids as candidate compounds can increase the chance of finding a specific agonist for the polypeptides of the present invention.
  • Another aspect of the invention relates to a method for changing the amyloid-beta precursor protein processing of a cell, comprising inhibiting the biological activity of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 15-28 and fragments, or derivatives thereof by contacting the cell with an expression inhibitory agent that inhibits the translation in the cell of a polyribonucleotide encoding the polypeptide.
  • Polypeptides of the present invention increase the level of pathological amyloid beta peptides. Inhibiting the activity of the polypeptide decreases the level of pathological amyloid beta peptides.
  • the expression inhibitory agent is selected from the group consisting of an antisense RNA, a ribozyme that cleaves the polyribonucleotide, an antisense oligodeoxynucleotide (ODN) , a small interfering RNA (siRNA) that is sufficiently homologous to a portion of the polyribonucleotide such that the siRNA is capable of inhibiting the polyribonucleotide that would otherwise cause the production of the polypeptide, and an antibody reactive to the polypeptide.
  • an antisense RNA a ribozyme that cleaves the polyribonucleotide
  • ODN antisense oligodeoxynucleotide
  • siRNA small interfering RNA
  • the expression inhibitory agent is a nucleic acid expressing the antisense RNA, a ribozyme that cleaves the polyribonucleotide, an antisense oligodeoxynucleotide (ODN) , a siRNA that is sufficiently homologous to a portion of a the polyribonucleotide such that the siRNA is capable of inhibiting the polyribonucleotide that would otherwise cause the production of the polypeptide, or an antibody reactive to the polypeptide
  • ODN antisense oligodeoxynucleotide
  • siRNA that is sufficiently homologous to a portion of a the polyribonucleotide such that the siRNA is capable of inhibiting the polyribonucleotide that would otherwise cause the production of the polypeptide
  • an antibody reactive to the polypeptide is a nucleic acid that is antisense to a nucleic acid comprising SEQ ID NO: 1-14.
  • an antisense nucleic acid e
  • DNA may be introduced into cells in vitro, or administered to a subject in vivo, as gene therapy to inhibit cellular expression of nucleic acids comprising SEQ ID NO: 1- 14.
  • Antisense oligonucleotides preferably comprise a sequence containing from about 17 to about 100 nucleotides and more preferably the antisense oligonucleotides comprise from about 18 to about 30 nucleotides.
  • Antisense nucleic acids may be prepared by expression of all or part of a sequence selected from the group consisting of SEQ ID NO: 1-14, in the opposite orientation.
  • Antisense oligonucleotides may also contain a variety of modifications that confer resistance to nucleolytic degradation such as, for example, modified internucleoside linkages, modified nucleic acid bases and/or modified sugars and the like.
  • the antisense oligonucleotides may also be modified by chemically linking the oligonucleotide to one or more moieties or conjugates to enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.
  • moieties or conjugates include lipids such as cholesterol, cholic acid, thioether, aliphatic chains, phospholipids, polyamines, polyethylene glycol (PEG), or palmityl moieties.
  • ribozymes relates to catalytic RNA molecules capable of cleaving other RNA molecules at phosphodiester bonds in a manner specific to the sequence.
  • the hydrolysis of the target sequence to be cleaved is initiated by the formation of a catalytically active complex consisting of ribozyme and substrate RNA. All ribozymes capable of cleaving phosphodiester bonds in trans, that is to say intramolecularly, are suitable for the purposes of the invention.
  • siRNAs small interfering RNAs
  • the nucleotide expressing the expression inhibitory agent is include'd within a vector.
  • the vector is an adenoviral, retroviral, adeno- associated viral, lentiviral or a sendaiviral vector.
  • the siRNA comprises a sense strand of 17- 23 nucleotides homologous to a 17-23 nucleotide long nucleotide sequence selected from the group consisting of SEQ
  • siRNA further comprises a loop region connecting the sense and the antisense strand.
  • a self-complementing single-stranded siRNA molecule according to the present invention comprises a sense portion and an antisense portion connected by a loop region.
  • the loop region is 4-30 nucleotides long, more preferably 5-15 nucleotides long and most preferably 8 nucleotides long.
  • the loop region consists of the sequence UUGCUAUA (SEQ ID NO: 339) .
  • Self-complementary single stranded siRNAs form hairpin loops and are more stable than ordinary dsRNA. In addition, they are more easily produced from vectors.
  • the expression inhibitory agent is an antisense RNA, ribozyme, antisense oligodeoxynucleotide, or siRNA comprising a nucleotide sequence selected from the group consisting of SEQ
  • a further aspect of the invention relates to a polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-338.
  • Another aspect of the present invention concerns a polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-338 for use as a medicament.
  • Yet another aspect of the present invention relates to the use of a polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-
  • Polynucleotides selected from the group consisting of
  • SEQ ID NO: 29-338 can be used in expression inhibitory agents inhibiting the expression of polypeptides of the present invention as described above.
  • the polynucleotide is a siRNA.
  • the invention relates to a vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-338.
  • the present invention relates to a vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-338 for use as a medicament .
  • the present invention relates to the use of a vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-338 for the manufacture of a medicament for the treatment of a disease involving cognitive impairment.
  • the vector encodes a siRNA, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 29-338.
  • the vector is an adenoviral, retroviral, adeno-associated viral, lentiviral or a sendaiviral vector.
  • the * disease is Alzheimer's disease.
  • the present invention concerns a method for diagnosing a pathological condition involving cognitive impairment or a susceptibility to the condition in a subject comprising: (a) obtaining a sample of the subject's mRNA corresponding to a nucleic acid selected from the group consisting of SEQ ID NO: 1-14, or a sample of the subject's genomic DNA corresponding to a genomic sequence of a nucleic acid selected from the group consisting of SEQ ID NO: 1-14 (b) determining the nucleic acid sequence of the subject's mRNA or genomic DNA; (c) comparing the nucleic acid sequence of the subject's mRNA or genomic DNA with a nucleic acid selected from the group consisting of SEQ ID NO: 1-14 or with a genomic sequence encoding a nucleic acid selected from the group consisting of SEQ ID NO: 1-14 obtained from a database; and (d) identifying any difference (s) between the nucleic acid sequence of the subject's mRNA or genomic DNA and the nucleic acid selected
  • the present invention relates to method for diagnosing a pathological condition involving cognitive impairment or a susceptibility to the condition in a subject, comprising determining the amount of polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15-28 in a biological sample, and comparing the amount with the amount of the polypeptide in healthy subjects, wherein an increase of the amount of polypeptide compared to the healthy subjects is indicative of the presence of the pathological condition.
  • the pathological condition is Alzheimer's disease .
  • amyloid beta peptide species refers to amyloid beta peptides with different composition that are processed from the amyloid beta precursor protein (APP) .
  • Examples of the species are 1-40, 1-42, y-42, whereby y ranges from 1-24, and 1-x whereby x ranges from 19-42.
  • expression comprises both endogenous expression and overexpression by transduction.
  • compound comprises organic and inorganic compounds, such as synthetic molecules, peptides, lipids, and natural compounds .
  • agonist refers to a ligand that activates the receptor the ligand binds to.
  • polypeptide relates to a protein, fractions of a protein, peptides, oligopeptides, or enzymes.
  • derivatives of a polypeptide relate to those peptides, oligopeptides, polypeptides, proteins and enzymes that comprise at least about 10 contiguous amino acid residues of the polypeptide and that retain the biological activity of the protein, e.g. polypeptides that have amino acid mutations compared to the amino acid sequence of a naturally-occurring form of the polypeptide.
  • a derivative may further comprise additional naturally-occurring, altered, glycosylated, acylated or non-naturally occurring amino acid residues compared to the amino acid sequence of a naturally- occurring form of the polypeptide. It may also contain one or more non-amino acid substituents compared to the amino acid sequence of a naturally-occurring form of the polypeptide, for example a reporter molecule or other ligand, covalentiy or non-covalently bound to the amino acid sequence.
  • fragment of a polypeptide relates to peptides, oligopeptides, polypeptides, proteins and enzymes that comprise at least about 5 contiguous amino acid residues, preferably at least 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 contiguous amino acid residues, and exhibit substantially a similar, but not necessarily identical, activity as the complete sequence.
  • polynucleotide refers to all nucleic acids, such as DNA and RNA, oligonucleotides. It also includes nucleic acids with modified backbones such as peptide nucleic acid, polysiloxane, and 2'-0-(2- methoxy) ethylphosphorothioate .
  • derivatives of a polynucleotide relates to DNA- and RNA- molecules, and oligonucleotides that comprise at least about 10 contiguous nucleic acid residues of the polynucleotide, e.g. polynucleotides that have nucleic acid mutations compared to the nucleic acid sequence of a naturally-occurring form of the polynucleotide.
  • a derivative may further comprise nucleic acids with modified backbones such as peptide nucleic acid (PNA) , polysiloxane, and 2 ' -0- (2-methoxy) ethyl-phosphorothioate, non-naturally occurring nucleic acid residues, or one or more nuclei acid substituents, such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl-, chloro-, and methanocarbanucleosides, or a reporter molecule to facilitate its detection.
  • PNA peptide nucleic acid
  • polysiloxane polysiloxane
  • 2 ' -0- (2-methoxy) ethyl-phosphorothioate non-naturally occurring nucleic acid residues
  • nuclei acid substituents such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl
  • fragment of a polynucleotide relates to oligonucleotides that comprise at least about 5 contiguous nucleic acid residues, preferably at least 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 contiguous nucleic acid residues, and exhibit substantially a similar, but not necessarily identical, activity as the complete sequence.
  • Figure legends Figure 1: APP processing: The membrane anchored amyloid precursor protein (APP) is processed by two pathways: the amyloidogenic and non amyloidogenic pathway. In the latter pathway, APP is cleaved first by alpha secretase and then by gamma secretase, yielding the p3 peptides (17-40 or 17-42) .
  • APP processing The membrane anchored amyloid precursor protein (APP) is processed by two pathways: the amyloidogenic and non amyloidogenic pathway. In the latter pathway, APP is cleaved first by alpha secretase and then by gamma secretase, yielding the p3 peptides
  • the amyloidogenic pathway generates the pathogenic amyloid beta peptides (A beta) after cleavage by beta- and gamma- secretase respectively.
  • the numbers depicted are the positions of the amino acids comprising the A beta sequences.
  • Figure 2 Evaluation of the APP processing assay:
  • LacZ and empty control viruses are infected in Hek293APPwt at random MOI, mimicking a screening.
  • a and B Transduction is performed respectively with 1 and 0.2 ⁇ l of virus and amyloid beta 1-42 levels are performed. Data are represented as relative light units and correlate to pM of amyloid beta 1-42.
  • Figure 3 Screening results: Hek293 APPwt cells are transduced with 0.2 ⁇ l of a collection of Ad5/GPCRs and amyloid beta 1-42 levels are monitored through ELISA. The data points from the plate comprising several Ad5/FPRL1 and Ad5/GCGR viruses are depicted.
  • Viruses scoring above the cutoff value which is calculated based on the formula [average + (3* standard deviation)] are considered as positives and thus stimulate amyloid beta production (1-42, 1-40) .
  • Data are represented as relative light units and correlate to pM of amyloid beta 1-42.
  • Figure 4 Confirmation of the involvement of FPRL1 and GCGR: Hek293 APPwt cells are transduced with Ad5/FPRL1, Ad5/GCGR and with 4 negative control viruses (Ad5/empty, Ad5/LacZ, Ad5/eGFP and Ad5/luciferase) at different MOIs (2- 1250) .
  • Resulting amyloid beta 1-42, 1-40 and 1-x peptides were measured with the appropriate ELISA' s. Data are represented in pM or as relative light units (rlu) , which correlates to pM of amyloid beta 1-x.
  • Figure 5 reporter gene analysis
  • A Glucagon dose response curve on HEK293 cells expressing the human glucagon receptor. Hek 293 cells are transduced with an adenovirus harboring the luciferase gene under the control of a cAMP dependent promoter and a virus harboring the glucagon receptor cDNA. 40 h after infection the cells were treated with increasing amounts of glucagon. Cells were lysed and the luciferase activity determined.
  • Glucagon has a pEC 50 value of 6.6. EC50 values were calculated with GraphPad Prism using non-linear regression.
  • Hek 293 cells are transduced with an adenovirus harboring the luciferase gene under the control of a cAMP dependent promoter (CRE elements) and a virus harboring the FPRLl receptor cDNA.
  • CRE elements cAMP dependent promoter
  • 40 h after infection the cells were treated with increasing amounts of fMLF and 10 ⁇ M forskolin. Cells were lysed and the luciferase activity determined.
  • fMLF has a pECso value of 7.4.
  • EC 50 values were calculated with GraphPad Prism using non-linear regression.
  • FIG. 6 effect of agonists: Hek293 APPwt cells are transduced with Ad5/GCGR (A), Ad5/FPRL1 (B) and Ad5/empty (A and B) , at a MOI of 50. After 24h, the viruses are removed and medium containing respectively 5nM glucagon (A) , ImM fMLF (B) or vehicle only is added. 24h later, the conditioned medium is collected and resulting amyloid beta 1-42 peptides were measured with the amyloid beta 1-42 ELISA. Data are represented as pM.
  • Figure.7 ClustalW protein sequence alignment of GCGR with its closest relatives, being GLPlR and GLP2R.
  • a second ClustalW alignment of the glucagon and the glucagon like peptides is shown.
  • table 6 the percentage of identity and similarity of other close homologues is shown.
  • Figure 8 ClustalW protein sequence alignment of FPRLl with its closest relatives, being FPR1 and FPRL2.
  • table 5 the percentage of identity and similarity of other close homologues is shown.
  • Ct values obtained during quantitative real time PCR Total human brain, human cerebral cortex or human hippocampus RNA is tested for the presence of FPRLl RNA via quantitative real time PCR. GAPDH RNA is used to normalize all samples (DCt) .
  • Glucagon receptor antagonist and agonist Antagonist Glucagon derivatives such as: [desHis (1) - [Glu (9) ] -glucagon-amide [desHis(l), Ala (4), Glu (9)] glucagon amide [desHis(l), D-Ala(4), Glu (9)] glucagon amide [desHis(l), Leu (4), Glu (9)] glucagon amide [desHis(l), D-Leu(4), Glu (9)] glucagon amide NNC 92-1687 BAY 27-9955 Alkylidene hydrazide derivatives with alkoxyaryl moieties such as: [4-hydroxy-3-cyanobenzoic acid (4- isopropylbenzyloxy-3, 5- dimethoxymethylene) hydrazide] 3-cyano-4-hydroxybenzoic acid [l-(2,3,5,6- tetramethylbenzyl) -lH-indol-4-ylm
  • Triarylimidazole and triarylpyrrole antagonist such as: 2- (-4-Pyridyl) -5- (4-chlorophenyl) -3- (5-bromo-2- propyloxyphenyl) pyrrole
  • EXAMPLE 1 GPCRs decrease amyloid beta 1-42 levels
  • a stable cell line overexpressing APP Hek293 APPwt
  • adenoviral cDNA libraries and the resulting amyloid beta 1-42 levels are detected via ELISA.
  • This stable cell line is created after transfection of Hek293 cells with the APP770wt cDNA cloned in pcDNA3.1 and selection with G418 during 3 weeks. At this time point colonies are picked and stable clones are expanded and tested for their secreted amyloid beta peptide levels.
  • the assay is performed as follows.
  • MOI average multiplicity of infection
  • the ELISA plate is prepared by coating the capture antibody (JRF/cAbeta42/26) (obtained from M Mercken, Johnson and Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium) overnight in buffer 42 (table 2) at a concentration of 2,5 ⁇ g/ml. The excess capture antibody is washed away the next morning with PBS and the ELISA plate is then blocked overnight with casein buffer (table 2) at 4°C. Upon removal of the blocking buffer, 30 ⁇ l of the sample is transferred to the ELISA plate and incubated overnight at 4°C.
  • the capture antibody JRF/cAbeta42/26)
  • HRP horse reddish peroxidase
  • JRF/AbetaN/25-HRP obtained from M Mercken, Johnson and Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium
  • HRP activity is detected via addition of luminol substrate (Roche) , which is converted into a chemiluminescent signal by the HRP enzyme.
  • adenoviral overexpression with random titre of two clinical PSl mutants and BACE on amyloid beta 1-42 production is evaluated in the Hek293 APPwt cells. As is shown in Figure 2, all constructs induce amyloid beta 1-42 levels as expected.
  • An adenoviral cDNA library containing almost all GPCRs was constructed as follows. DNA fragments covering the full coding region of the GPCRs, are amplified by PCR from a pooled placental and fetal liver cDNA library (InvitroGen) .
  • amyloid beta 1-40 and 1-x levels are checked under similar conditions as above.
  • the respective ELISA' s are performed as described above, except that the following antibodies were used: for the amyloid beta 1-40 ELISA, the capture and detection antibody are respectively JRF/cAbeta40/10 and JRF/AbetaN/25-HRP (obtained from M Mercken, Johnson and Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium) , while for the amyloid beta 1-x ELISA (x ranges from 19-42) the capture and detection antibodies are JRF/AbetaN/25 and 4G8-HRP, respectively (obtained respectively from M Mercken, Johnson and Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium and from Signet, USA) .
  • amyloid beta 1-x ELISA is used for the detection of amyloid peptides with a variable C- terminus (amyloid beta 1-37; 1-38; 1-39; 1-40; 1-42).
  • the results of these experiments clearly show an increase of amyloid beta 1-40 and 1-x species upon transduction of FPRLl and GCGR (figure 4B and 4C) .
  • FPRLl is known as a GPCR that has both endogenous peptide and lipid (lipoxin A4) ligands. At least three host-derived polypeptides are identified as ligands for this receptor, which are all associated with amyloidogenic diseases: serum amyloid A, prion protein fragmentl06-126 and amyloid beta 1- 42.
  • FPRLl a chemotactic receptor for amyloid beta 1-42, which induces monocyte migration and activation.
  • mononuclear phagocytes that surround or infiltrate the plaques express high levels of FPRLl.
  • FPRLl can promote the cellular uptake of amyloid beta 1-42 by rapid internalisation into the cytoplasmic compartment in the form of amyloid beta 1-42- FPRLl complexes.
  • amyloid fibrils and aggregates are accumulated in macrophages in an FPRLl-mediated fashion.
  • EXAMPLE 2 Identification of close relatives of FPRLl and GCGR.
  • the amino acid sequence of the human GCGR receptor was used as query in a BLAST search against all the human GPCRs in order to find its closest homologues.
  • Table 6 shows the 5 closest homologues of the glucagon receptor.
  • ClustalW an alignment was constructed showing the degree of homology between the GCGR and its closest homologues, the GLPRl and GLPR2 (fig. 7) .
  • the amino acid sequence of the human FPRLl receptor was used as query in a BLAST search against all the human GPCRs in order to find its closest homologues.
  • Table 5 shows the 5 closest homologues of the FPRLl receptor.
  • ClustalW an alignment was constructed showing the degree of homology between the GCGR and its closest homologues, the FPRl and FPRL2 (fig 8) .
  • EXAMPLE 3 Functional analysis of GPCR receptors in HEK293 cells by reporter gene analysis. All GPCRs share a common architecture of 7 transmembrane domains, an extracellular N-terminus and an intracellular C- terminus. The major signal transduction cascades activated by GPCRs are initiated by the activation of heterotrimeric G- proteins (Wess (1998) ) . In addition, minor signal transduction pathways that are G-protein independent exist (Marinissen and Gutkind (2001)). Heterotrimeric G-proteins are built from three different proteins; the G ⁇ , G ⁇ and G ⁇ subunits. The signal transduction cascade starts with the activation of the receptor by an agonist. Transformational changes in the receptor are then translated down to the G- protein.
  • the G-protein dissociates into the G ⁇ subunit and the G ⁇ subunit. Both subunits dissociate from the receptor and are both capable of initiating different cellular responses. Best known are the cellular effects that are initiated by the G ⁇ subunit. It is for this reason that G- proteins are categorized by their G ⁇ subunit.
  • the G-proteins are divided into four groups: G s ,G ⁇ /0 , G q and G ⁇ 2/ ⁇ 3 . Each of these G-proteins is capable of activating an effector protein, which results in changes in second messenger levels in the cell. The changes in second messenger level are the triggers that make the cell respond to the extracellular signal in a specific manner.
  • Inositol 1, 4, 5-trisphosphate binds specific receptors in the endoplasmatic reticulum, resulting in the opening of Ca 2+ channels and release of Ca 2+ in the cytoplasm.
  • Receptor activation can be measured by several different techniques. Usually these measurements detect the levels of second messengers either directly by ELISA or radioactive technologies or indirectly by reporter gene analysis.
  • Reporter gene technology consists of an easily detectable gene, such as luciferase or ⁇ -galactosidase under the regulation of a promoter that responds to the cellular level of second messengers.
  • a luciferase gene placed under the control of a minimal promoter regulated by cAMP responsive elements (CRE) .
  • CRE cAMP responsive elements
  • cAMP binds to the regulatory subunit of protein kinase A (PKA) and by forcing the subunit to dissociate from the catalytic subunit cAMP activates PKA.
  • PKA protein kinase A
  • CREB cAMP responsive element binding protein
  • CREB Upon phosphorylation, CREB translocates to the nucleus and binds to CRE DNA sequences in promoter regions, initiating transcription of downstream genes. Activation of G s by a GPCR will thus result in an increase in luciferase activity when the reporter gene construct is present in the same cell as the receptor.
  • a similar reporter gene is constructed for the measurement of changes in intracellular Ca 2+ levels. This reporter makes use of the Ca 2+ dependent activation of the transcription factor NF-AT (nuclear factor activated T- cells) . To activate this transcription factor Ca 2+ must activate calcineurin, which in turn acts as a phosphatase for NF-AT.
  • NF-AT The dephosphorylated form of NF-AT translocates to the nucleus and binds specific promoter elements. Binding of NF-AT to these cis-acting elements drives the transcription of a downstream gene, in our case the luciferase gene.
  • a downstream gene in our case the luciferase gene.
  • adenoviral vector By doing so we can make an adenovirus and use this virus to introduce the reporter gene construct into our assay cells with the purpose to measure GPCR activation.
  • Adenoviruses are constructed harboring the luciferase gene under the control of a minimal promoter with respectively CRE elements or NF-AT responsive elements.
  • HEK293 cells are transduced with adenoviruses containing GPCRs and either the CRE reporter or the NF-AT reporter, .
  • adenoviruses containing GPCRs and either the CRE reporter or the NF-AT reporter In general cells are plated in a 96 well plate at a density of 10,000 cells per well in Dulbeco's modified Eagles medium (DMEM) supplemented with 10% fetal calf serum (FCS) . After the cells are firmly attached, GPCR or control viruses expressing eGFP and LacZ, are added to the cells with a MOI of 50. Subsequently reporter virus is added at an MOI of 400. The cells are incubated for 18 h with the virus before the virus is washed away and the medium replaced with DMEM, 5% FCS.
  • DMEM Dulbeco's modified Eagles medium
  • FCS fetal calf serum
  • the cells are left for an additional 24 h before they are treated with increasing amounts of agonist (glucagon or fMLF) for a period of 6 h after which the cells are lysed and the luciferase activity is measured using the steady light kit from Packard according to the manufacturer's protocol .
  • Stimulation of GCGR with increasing amounts of glucagon shows a dose dependent increase in luciferase activity indicating that activation of the glucagon receptor results in an increase of intracellular cAMP (fig. 5A) and NF-AT (fig. 5B) . This result indicates that the glucagon receptor couples in HEK 293 cells to G s and G-protein giving rise to increased intracellular Ca 2+ - levels.
  • Stimulation of FPRLl with increasing amounts of fMLF shows a dose dependent decrease in luciferase activity indicating that activation of the FPRLl receptor results in an decrease of intracellular cAMP (fig. 5C) .
  • Forskoline (10 ⁇ M) was added simultaneously with the ligand to increase the basal cAMP content of the cells so that a larger window of detection is created. This result indicates that the formyl petpide receptor couples in HEK 293 cells to Gn- 3 or G 0 .
  • EXAMPLE 4 Effect on amyloid beta peptide production by an agonist activated G protein coupled receptor. Whereas overexpression of GPCRs results in constitutive signalling, the activity of endogenous GPCRs is normally modulated by binding of natural occurring agonists or antagonists. Because this is why they are good drug targets, it is of great value for future therapeutic applications to show that amyloid beta levels can be modulated by the agonists or antagonists of the GPCRs. Therefore, the effect of the fMLF (agonist for FPRLl) and glucagon peptides (agonist for GCGR) on amyloid beta levels are evaluated in the Hek293 APPwt cells.
  • fMLF agonist for FPRLl
  • glucagon peptides agonist for GCGR
  • Hek293 APPwt cells are transduced with respectively Ad5/empty, Ad5/GCGR and Ad5/FPRL1 at an MOI of 50 during 24 h. Viruses are washed away and fresh medium containing respectively 5nM glucagon and ImM fMLF is added to the cells. 24h later, the conditioned medium is assayed in the amyloid beta 1-42 ELISA as described in example 1. It is observed that the addition of 5nM glucagon to cells transduced with Ad5/GCGR results in a 2 fold increase of amyloid beta 1-42 levels compared to un- stimulated cells transduced with either Ad5/GCGR or
  • Ad5/empty indicating that an agonist of GCGR is able to modulate amyloid beta 1-42 levels (figure 6A) .
  • stimulating Hek293 APPwt cells, that are transduced with Ad5/FPRL1, with ImM fMLF yields an increase in the amyloid beta 1-42 levels compared to un-stimulated cells transduced with either Ad5/FPRL1 or Ad5/empty, indicating that an agonist of FPRLl is able to modulate amyloid beta 1-42 levels (figure 6B) .
  • antagonists for FPRLl and GCGR are tested to evaluate whether inhibiting the GPCRs results in a decrease of the amyloid beta 1-42 levels.
  • Hek293 APPwt cells are infected with respectively Ad5/empty, Ad5/GCGR and Ad5/FPRL1 during 24 h. Viruses are washed away and fresh medium containing respectively 5nM glucagon +/- antagonist and ImM fMLF +/- antagonist are added to the cells. 24h later, the conditioned medium is assayed in the amyloid beta 1-42 ELISA as described in example 1.
  • EXAMPLE 5 Expression of GPCRs in the human brain Upon identification of a modulator of APP processing, it is of the highest importance to evaluate whether the modulator is expressed in the tissue and the cells of interest. This can be achieved by measuring the RNA and/or protein levels. In recent years, RNA levels are being quantified through real time PCR technologies, whereby the RNA is first transcribed to cDNA and then the amplification of the cDNA of interest is monitored during a PCR reaction. The amplification plot and the resulting Ct value are indicators for the amount of RNA present in the sample. Determination of the levels of household keeping genes allows the normalization of RNA levels of the target gene between different RNA samples, represented as delta Ct values.
  • the resulting cDNA is amplified with AmpliTaq Gold DNA polymerase (Applied BioSystems) during 40 cycles using an ABI PRISM® 7000 Sequence Detection System.
  • Total brain, cerebral cortex and hippocampal total RNA are analyzed for the presence of GPCR transcripts of table 1 via quantitative real time PCR.
  • the obtained Ct values indicate that it is detected in all RNA samples (table 4) .
  • immunohistochemistry (protein level) and/or in situ hybridization (RNA level) are carried out on sections from a human normal and Alzheimer's brain hippocampal, cortical and subcortical structures. These results indicate whether expression occurs in neurons, microglia cells or astrocytes.
  • EXAMPLE 6 Amyloid beta production in rat primary neuronal cells
  • human or rat primary hippocampal or cortical neurons are transduced with adenoviruses containing the GPCRs.
  • Amyloid beta levels are determined by ELISA and mass spectrometry analysis (see EXAMPLE 6) . Since rodent APP genes carry a number of mutations in APP compared to the human sequence, they produce less amyloid beta 1-40 and 1-42.
  • Human primary neurons are purchased from Cellial Technologies, France. Rat primary neuron cultures are prepared from brain of E18-El9-day-old fetal Sprague Dawley rats according to Goslin and Banker (Culturing Nerve cells, second edition, 1998 ISBN 0-262-02438-1) . Briefly, single cell suspensions obtained from the hippocampus or cortices are prepared.
  • the number of cells is determined (only taking into account the living cells) and cells are plated on poly- L-lysine-coated plastic 96-well plates in minimal essential medium (MEM) supplemented with 10% horse serum.
  • MEM minimal essential medium
  • the cells are seeded at a density between 30,000 and 60,000 cells per well (i.e. about 100,000 - 200,000 cells/cm 2 , respectively).
  • culture medium was replaced by 150 ⁇ l serum-free neurobasal medium with B27 supplement (GIBCO BRL) .
  • Cytosine arabinoside (5 ⁇ M) was added 24 h after plating to prevent nonneuronal (glial) cell proliferation. Neurons are used at day 5-7 after plating.
  • adenoviral transduction 150 ⁇ l conditioned medium of these cultures is transferred to the corresponding wells in an empty 96-well plate and 50 ⁇ l of the conditioned medium returns to the cells. The remaining 100 ⁇ l/well is stored at 37 °C and 5% C0 2 . Both hippocampal and cortical primary neuron cultures are coinfected with the crude lysate of virus containing the cDNAs of the GPCRs, and human wild type APP or human Swedish mutant APP, at different MOIs, ranging from 100 to 3000. Sixteen to twenty-four hours after transduction, virus is removed and cultures are washed with 100 ⁇ l pre- warmed fresh neurobasal medium.
  • the remaining 100 ⁇ l of the stored conditioned medium is transferred to the corresponding cells.
  • cells accumulate amyloid beta in the conditioned medium and its concentration is determined by amyloid beta 1-42 and Amyloid beta x-42 specific ELISA' s (see EXAMPLE 1).
  • the conditioned media are collected 24, 48 and 96 hours after exchanging virus-containing medium by stored conditioned medium.
  • EXAMPLE 7 Amyloid beta peptides profiling in conditioned medium of GPCRs of the invention infected HEK293 APP770wt cells and rat primary neuronal cells using Mass Spectrometry
  • a mass spectrometry analysis is carried out on the conditioned medium of cells overexpressing the latter GPCRs or cells into which the activity of the endogenous GPCR is inhibited with its antagonist, to identify the inhibited amyloid beta peptide species .
  • T25 flasks (Cellstar, Greiner Bio-One) are coated with collagen (5 ⁇ g/ml) for 4h at 37 °C.
  • HEK293 APP770wt cells are seeded at a density of 3.10 6 cells per flask. Cells are grown overnight at 37 °C, 10% C0 2 . Next day, cells are infected with the crude lysate of virus containing the cDNAs of the GPCRs at the appropriate MOI. The cells are incubated at 37 °C, 10% C0 2 . After 12 to 24 hours, the cell culture medium is removed by aspiration and 3 ml of fresh medium (DMEM, 0.2% FBS, IX ITS from GIBCO) is added to the cells. 24 hours later, the conditioned medium is harvested.
  • DMEM 0.2% FBS, IX ITS from GIBCO
  • Protease inhibitors are added immediately and the samples are kept on ice in Falcon tubes until further processing. Of each sample, 850 ⁇ l of the conditioned medium is transferred to an eppendorf tube in triplet. After rigorously vortexing the Protein G Sepharose beads, 5 ⁇ l of the slurry is added to each tube, together with 1 ⁇ g of specific antibody e.g. 4G8 or JRF/cAbeta42/26 (obtained from M Mercken, Johnson and Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium) . Tubes are rotated overnight at 4°C and centrifuged for 10 min. All centrifuge steps are at 13200 rp at 4°C.
  • specific antibody e.g. 4G8 or JRF/cAbeta42/26
  • beads are washed twice by adding 850 ⁇ l of wash buffer (10 mM Tris-HCI (pH 8.0) containing 0.1% n- octylglucoside, 150 mM NaCI, 0.025% sodium azide) and centrifuging for 10 min.
  • wash buffer 10 mM Tris-HCI (pH 8.0) containing 0.1% n- octylglucoside, 150 mM NaCI, 0.025% sodium azide
  • 850 ⁇ l of 10 mM Tris-HCI (pH 8.0) cells are centrifuged for 10 min and supernatant is removed completely. Dry pellets are stored at -80 °C until further analysis.
  • a saturated solution of matrix alpha-cyano-hydroxy- cinnamic acid, HCCA is prepared in 500 ⁇ l acetonitrile by vortexing.
  • the target plate is inserted into the MALDI-TOF-TOF mass spectrometer and measurements are performed according to the MALDI-TOF instructions.
  • the resulting spectra are calibrated using a standard curve acquired using a mixture of several standard peptides obtained from Sigma. These standard peptides are in the mass range of 1200 - 3200 Da.
  • EXAMPLE 8 Ligand screen for GPCRs Reporter gene screen Mammalian cells such as HEK293 or CHO-K1 cells are either stably transfected with a plasmid harboring the luciferase gene under the control of a cAMP dependent promoter (CRE elements) or transduced with an adenovirus harboring a luciferase gene under the control of a cAMP dependent promoter.
  • CRE elements cAMP dependent promoter
  • reporter constructs can be used with the luciferase gene under the control of a Ca 2+ dependent promoter (NF-AT elements) or a promoter that is controlled by activated NF- ⁇ B.
  • These cells, expressing the reporter construct, are then transduced with an adenovirus harboring the cDNA of the GPCR of the present invention. 40 h after transduction the cells are treated with an agonist for the receptor (table 7 and 8) and screened against a large collection of reference compounds comprising peptides (LOPAP, Sigma Aldrich) , lipids (Biomol, TimTech) , carbohydrates (Specs), natural compounds (Specs, TimTech), and small chemical compounds (Tocris) .
  • Compounds, which decrease the agonist induced increase in luciferase activity are considered to be antagonists or inverse agonists for the GPCR they are screened for.
  • G 15 is a promiscuous G protein of the G q class that couples to many different GPCRs and as such re-directs their signaling towards the release of intracellular Ca 2+ stores.
  • the chimerical G alpha subunits are members of the G s and Gi /0 family by which the last 5 C-terminal residues are replaced by those of G ⁇ q, these chimerical G-proteins also redirect cAMP signaling to Ca 2+ signaling.
  • FLIPR screen Mammalian cells such as HEK293 or CHO-Kl cells are stably transfected with a expression plasmid construct harboring the cDNA of a GPCR of the present invention. Cells are seeded and grown until sufficient stable cells can be obtained. Cells are loaded with a Ca 2+ dependent fluorophore such as Fura3 or Fura4.
  • the cells are screened against a large collection of reference compounds comprising peptides (LOPAP, Sigma Aldrich) , lipids (Biomol, TimTech) , carbohydrates (Specs) , natural compounds (Specs, TimTech) , and small chemical compounds (Tocris) by simultaneously adding an agonist (Table 7) and a compound to the cells.
  • LOPAP peptides
  • lipids Biomol, TimTech
  • carbohydrates Specs
  • Specs, TimTech natural compounds
  • small chemical compounds Tocris
  • Activation of the receptor is measured as an almost instantaneously increase in fluorescence due to the interaction of the fluorophore and the Ca 2+ that is released.
  • Compounds that reduce or inhibit the agonist induced increase in fluorescence are considered to be antagonists or inverse agonists for the receptor they are screened against.
  • AequoScreen CHO cells stably expressing Apoaequorin are stably transfected with a plasmid construct harboring the cDNA of a GPCR. Cells are seeded and grown until sufficient stable cells can be obtained. The cells are loaded with coelenterazine, a cofactor for apoaequorin. Upon receptor activation intracellular Ca 2+ stores will be emptied and the aequorin will react with the coelenterazine in a light emitting process. The emitted light is a measure for receptor activation.
  • the CHO, stable expressing both the apoaequorin and the receptor are screened against a large collection of reference compounds comprising peptides (LOPAP, Sigma Aldrich), lipids (Biomol, TimTech), carbohydrates (Specs), natural compounds (Specs, TimTech) , and small chemical compounds (Tocris) by simultaneously adding an agonist and a compound to the cells.
  • LOPAP peptides
  • Biomol, TimTech lipids
  • carbohydrates Specs
  • Natural compounds Specs, TimTech
  • small chemical compounds Tocris
  • Activation of the receptor is measured as an almost instantaneously light flash due to the interaction of the apoaequorin, coelenterazine and the Ca 2+ that is released.
  • Compounds that reduce or inhibit the agonist induced increase in light are considered to be antagonists or inverse agonists for the receptor they are screened against.
  • CHO cells stable expressing the apoaequorin gene are stably transfected with a plasmid construct harboring the cDNA encoding the ⁇ -subunit of G ⁇ 5 or chimerical G ⁇ subunits.
  • G 15 is a promiscuous G protein of the G q class that couples to many different GPCRs and as such redirect their signaling towards the release of intracellular Ca2+ stores.
  • the chimerical G alpha subunits are members of the G s and G ⁇ /0 family by which the last 5 C-terminal residues are replaced by those of G ⁇ q , these chimerical G-proteins also redirect cAMP signaling to Ca2+ signaling.
  • Screening for compounds that bind to the polypeptides of the present invention Compounds are screened for binding to the polypeptides of the present invention. The affinity of the compounds to the polypeptides is determined in a displacement experiment. In brief, the polypeptides of the present invention are incubated with a labeled (radiolabeled, fluorescent labeled) ligand that is known to bind to the polypeptide and with an unlabeled compound.
  • the displacement of the labeled ligand from the polypeptide is determined by measuring the amount of labeled ligand that is still associated with the polypeptide.
  • the amount associated with the polypeptide is plotted against the concentration of the compound to calculate IC 50 values. This value reflects the binding affinity of the compound to its target, i.e. the polypeptides of the present invention. Strong binders have an IC50 in the nanomolar and even picomolar range.
  • Compounds that have an IC 50 of at least 10 micromol or better (nmol to pmol) are applied in beta amyloid secretion assay to check for their effect on the beta amyloid secretion and processing.
  • polypeptides of the present invention can be prepared in a number of ways depending on whether the assay will be run on cells, cell fractions or biochemically, on purified proteins.
  • Receptor ligand binding study on cell surface The receptor is expressed in malian cells (HEK293,
  • CHO, COS7 cells by adenovirally transducing the cells (see US 6,340,595).
  • the cells are incubated with both labeled ligand (iodinated, tritiated, or fluorescent) and the unlabeled compound at various concentrations, ranging from 10 pM to lO ⁇ M (3 hours at 4°C: 25 mM HEPES, 140 mM NaCI, 1 mM
  • Membranes preparations are isolated from mammalian cells (HEK293, CHO, COS7) cells overexpressing the receptor is done as follows: Medium is aspirated from the transduced cells and cells are harvested in 1 x PBS by gentle scraping. Cells are pelleted (2500 rpm 5 min) and resuspended in 50 mM Tris pH 7.4 (10 x 10E6 cells/ml). The cell pellet is homogenized by sonicating 3 x 5 sec (UP50H; sonotrode MSI; max amplitude: 140 ⁇ m; max Sonic Power Density: 125W/cm 2 ) .
  • Membrane fractions are prepared by centrifuging 20 min at maximal speed (13000 rpm -15 000 to 20 OOOg or rcf) . The resulting pellet is resuspended in 500 ⁇ l 50 mM Tris pH 7.4 and sonicated again for 3 x 5 sec. The membrane fraction is isolated by centrifugation and finally resuspended in PBS. Binding competition and derivation of IC 50 values are determined as described above.
  • EXAMPLE 9 Inhibition of the GPCR mediated effect on amyloid beta production via knock down of the GPCR expression levels .
  • the effect of an antagonist can be mimicked through the use of siRNA based strategies, which result in decreased expression levels of the targeted protein.
  • Adenoviral mediated siRNA or knock down constructs based upon the sequences shown in table 9, are constructed as described in WO03020931.
  • Cell lines e.g. Hek293, SH-SY5Y, IMR-32, SK-N- SH, SK-N-MC, H4, CHO, COS, HeLa
  • stably overexpressing APPwt or not, or rat primary neuronal cells are transduced with these adenoviral knock down constructs.
  • the adenoviruses are removed and fresh medium is added to the cells.
  • the medium of the cells is refreshed to allow the accumulation of amyloid beta 1-42 peptides.
  • the conditioned medium of these cells is assayed in the amyloid beta 1-42 ELISA, which is performed as described in example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention se rapporte à des procédés pour identifier un composé qui modifie le traitement d'une protéine précurseur de la bêta-amyloïde dans une cellule. Cette invention concerne également des procédés pour modifier le traitement d'une protéine précurseur de la bêta-amyloïde dans une cellule, ainsi qu'un procédé permettant de diagnostiquer, chez un sujet, un état pathologique impliquant une déficience cognitive ou une prédisposition à cet état.
PCT/EP2003/010160 2003-09-10 2003-09-10 Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule WO2005024057A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/EP2003/010160 WO2005024057A1 (fr) 2003-09-10 2003-09-10 Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule
AU2003267347A AU2003267347A1 (en) 2003-09-10 2003-09-10 Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
PCT/EP2004/010172 WO2005024058A2 (fr) 2003-09-10 2004-09-10 Composes destines au traitement de maladies provoquant un trouble cognitif, telles que la maladie d'alzheimer et methodes permettant d'identifier ces composes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/010160 WO2005024057A1 (fr) 2003-09-10 2003-09-10 Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule

Publications (1)

Publication Number Publication Date
WO2005024057A1 true WO2005024057A1 (fr) 2005-03-17

Family

ID=34259125

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/010160 WO2005024057A1 (fr) 2003-09-10 2003-09-10 Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule
PCT/EP2004/010172 WO2005024058A2 (fr) 2003-09-10 2004-09-10 Composes destines au traitement de maladies provoquant un trouble cognitif, telles que la maladie d'alzheimer et methodes permettant d'identifier ces composes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010172 WO2005024058A2 (fr) 2003-09-10 2004-09-10 Composes destines au traitement de maladies provoquant un trouble cognitif, telles que la maladie d'alzheimer et methodes permettant d'identifier ces composes

Country Status (2)

Country Link
AU (1) AU2003267347A1 (fr)
WO (2) WO2005024057A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047899A2 (fr) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
WO2005103708A1 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et traitement de maladies associees recepteur couple a la proteine g humaine ressemblant a gpr-32
WO2005106490A1 (fr) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees au recepteur 1 de type chimiokine (cmklr1)
US7198912B2 (en) 2001-09-07 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding a human G-protein coupled receptor, HGPRBMY39
WO2008028250A1 (fr) * 2006-09-08 2008-03-13 Autogen Research Pty Ltd Agents thérapeutiques, cibles et diagnostique
US7671028B2 (en) * 2004-02-04 2010-03-02 Postech Foundation Peptides that antagonize FPR class receptor mediated signaling

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103255A1 (fr) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteur formylpeptide (fpr) utilise en tant que cible pour une therapie anti-gliome malin
CN101586103B (zh) * 2009-06-25 2010-12-08 上海交通大学 胰高血糖素受体基因的rna干扰序列
CN104274817B (zh) * 2014-09-25 2016-06-15 中山大学 Wrw三肽在制备治疗阿尔茨海默症药物中的用途
CN104258371B (zh) * 2014-09-25 2016-06-15 中山大学 Www三肽在制备治疗阿尔茨海默症药物中的用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083553A2 (fr) * 2000-05-03 2001-11-08 Pharmacia & Upjohn Company Nouveaux recepteurs couples a la proteine g
WO2002029052A2 (fr) * 2000-10-06 2002-04-11 Bayer Aktiengesellschaft Regulation du recepteur de secretine humaine de type gpcr
WO2002044212A2 (fr) * 2000-11-30 2002-06-06 Deleersnijder, Willy Recepteur couple aux proteines g humaines et ses utilisations
WO2003035684A1 (fr) * 2001-10-18 2003-05-01 Axaron-Bioscience Ag Famille de proteines ee3 et sequences d'adn correspondantes
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
WO2003065045A2 (fr) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur gpr65
WO2003074069A2 (fr) * 2002-03-07 2003-09-12 Bayer Healthcare Ag Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2003080098A2 (fr) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics et therapeutiques associes au recepteur 2 du peptide de formyle humain
WO2003082314A2 (fr) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
WO2003096024A1 (fr) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Diagnostics et traitements pour maladies associees au recepteur 2 du peptide intestinal vasoactif (vpac2)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028631A2 (fr) * 2001-09-21 2003-04-10 Accera, Inc. Cibles medicamenteuses destinees a la maladie d'alzheimer et a d'autres maladies associees a une diminution du metabolisme neuronal
US7329683B2 (en) * 2002-02-01 2008-02-12 Merck & Co., Inc. 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
JP4475406B2 (ja) * 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
DE60332738D1 (de) * 2002-07-30 2010-07-08 Merck Sharp & Dohme Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
WO2004094636A1 (fr) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Constructions demontables effectives d'arnsi

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083553A2 (fr) * 2000-05-03 2001-11-08 Pharmacia & Upjohn Company Nouveaux recepteurs couples a la proteine g
WO2002029052A2 (fr) * 2000-10-06 2002-04-11 Bayer Aktiengesellschaft Regulation du recepteur de secretine humaine de type gpcr
WO2002044212A2 (fr) * 2000-11-30 2002-06-06 Deleersnijder, Willy Recepteur couple aux proteines g humaines et ses utilisations
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
WO2003035684A1 (fr) * 2001-10-18 2003-05-01 Axaron-Bioscience Ag Famille de proteines ee3 et sequences d'adn correspondantes
WO2003065045A2 (fr) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur gpr65
WO2003074069A2 (fr) * 2002-03-07 2003-09-12 Bayer Healthcare Ag Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2003080098A2 (fr) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics et therapeutiques associes au recepteur 2 du peptide de formyle humain
WO2003082314A2 (fr) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
WO2003096024A1 (fr) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Diagnostics et traitements pour maladies associees au recepteur 2 du peptide intestinal vasoactif (vpac2)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LE Y ET AL: "PLEIOTROPIC ROLES OF FORMYL PEPTIDE RECEPTORS", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 12, no. 1, March 2001 (2001-03-01), pages 91 - 105, XP001133719, ISSN: 1359-6101 *
NITSCH R M ET AL: "REGULATION OF PROTEOLYTIC PROCESSING OF THE AMYLOID BETA-PROTEIN PRECURSOR BY FIRST MESSENGERS", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR. AULENDORF, DE, vol. 45, no. 32, 1995, pages 435 - 438, XP002054765, ISSN: 0004-4172 *
YAZAWA HIROSHI ET AL: "beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages", FASEB JOURNAL, vol. 15, no. 13, November 2001 (2001-11-01), pages 2454 - 2462, XP002280686, ISSN: 0892-6638 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198912B2 (en) 2001-09-07 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding a human G-protein coupled receptor, HGPRBMY39
US7417121B2 (en) 2001-09-07 2008-08-26 Bristol-Myers Squibb Company Human G-protein coupled receptor, HGPRBMY39
WO2005047899A2 (fr) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
WO2005047899A3 (fr) * 2003-11-07 2006-03-30 Acadia Pharm Inc Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
US7671028B2 (en) * 2004-02-04 2010-03-02 Postech Foundation Peptides that antagonize FPR class receptor mediated signaling
WO2005103708A1 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et traitement de maladies associees recepteur couple a la proteine g humaine ressemblant a gpr-32
WO2005106490A1 (fr) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees au recepteur 1 de type chimiokine (cmklr1)
WO2008028250A1 (fr) * 2006-09-08 2008-03-13 Autogen Research Pty Ltd Agents thérapeutiques, cibles et diagnostique

Also Published As

Publication number Publication date
WO2005024058A2 (fr) 2005-03-17
WO2005024058A3 (fr) 2005-11-10
AU2003267347A1 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
US20050287565A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7910320B2 (en) Methods compositions and compound assays for inhibiting amyloid-beta protein production
Vogt et al. ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth
EP2167692B1 (fr) Variants d'épissage de cd44 dans des maladies neurodégénératives
JP2009525046A (ja) アルファ−シヌクレインキナーゼ
WO2005119262A2 (fr) Procedes, compositions et essais sur composes pour l'inhibition de la production de la proteine beta-amyloide
WO2005024057A1 (fr) Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule
US20200138951A1 (en) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
US20140256790A1 (en) Methods for Identifying and Compounds Useful for Increasing the Functional Activity and Cell Surface Expression of CF-Associated Mutant Cystic Fibrosis Transmembrance Conductance Regulator
WO2005103689A1 (fr) Nouveaux composes permettant de traiter la maladie d'alzheimer et leurs methodes
US20050277612A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103693A2 (fr) Procedes, compositions et dosages de composes destines a inhiber la production de proteine $g(b)-amyloide
WO2005103707A1 (fr) Nouveaux composes destines au traitement de la maladie d'alzheimer et procedes d'identification desdits composes
WO2005103715A2 (fr) Procedes, compositions et dosages de composes destines a inhiber la production de proteine $g(b)-amyloide
US8110348B2 (en) Methods and compositions for the diagnosis and treatment of schizophrenia
JP2001066302A (ja) 細胞死抑制薬の同定方法およびスクリーニング方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP